Loading quotes...

Forecast

The analysts' average price target is €172.54 (+106.98%). The median is €171.11 (+105.27%).

Buy	33
Hold	2
Sell	1

News Go to news feed

Parnassus exits Insmed after Brinsupri sales fall short, reallocates to Twist Bioscience

Parnassus Growth Equity Fund sold its stake in Insmed, citing that the investment thesis had largely played out after positive TPIP data and prior upward revisions to Brinsupri sales. The fund said Insmed shares fell when Brinsupri sales missed analysts' expectations and redeployed the proceeds into Twist Bioscience for a longer growth runway. Insmed shares have declined recently and trade well below their 52-week high. » More on finance.yahoo.com
Insmed raises guidance after strong BRINSUPRI launch

At the Morgan Stanley conference Insmed reported that the BRINSUPRI launch is exceeding expectations and the annual sales forecast for the drug has been raised to $1.25–1.4 billion. The company sees U.S. peak sales potential for BRINSUPRI of over $7 billion and raised the peak sales estimate for TPIP to more than $6 billion. Japan is being expanded as an important international growth market, while Europe is waiting for clear reimbursement conditions. Management also cites pipeline progress, the use of AI and gene therapy programs as drivers, but points to risks from competition and reimbursement issues. » More on de.investing.com
Insmed flagged as largest detractor by Artisan despite strong Brinsupri launch

Artisan Global Opportunities said Insmed was its biggest detractor in Q2 after trimming the position, citing Q1 sales modestly below elevated expectations due to concerns around discontinuation, therapy continuation and seasonality. The firm still views BRINSUPRI®'s rapid launch and uptake as encouraging and believes the therapy is on track for blockbuster-level sales and remains well tolerated. Insmed closed at $121.51 on Sept 1, returned 25.42% over the past month, is down 13.45% over 52 weeks, and has a market capitalization of $27.14 billion. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Insmed has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Insmed had revenue of €372.82M and net profit of -€11.6M

(EUR)	June 2026	YoY
Revenue	372.82M	309.09%
Gross profit	313.92M	366.36%
Net profit	-11.6M	95.75%
EBITDA	12.41M	104.92%

Fundamentals

Metric	Value
Market capitalization	€18.18B
Number of shares	218.38M
52-week high/low	€189.60 - €80.56
Dividends	No
Beta	0.82
P/E ratio	-22.72
PEG ratio	-0.90
P/B ratio	26.80
P/S ratio	17.93

Company profile

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.